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Abstract: Primary amoebic encephalitis (PAM) caused by the opportunistic pathogen Naegleria fowleri
is characterized as a rapid and lethal infection of the brain which ends in the death of the patient
in more than 90% of the reported cases. This amoeba thrives in warm water bodies and causes
infection after individuals perform risky activities such as splashing or diving, mostly in non-treated
water bodies such as lakes and ponds. Moreover, the infection progresses very fast and no fully
effective molecules have currently been found to treat PAM. In this study, naphthyridines fused with
chromenes or chromenones previously synthetized by the group were tested in vitro against the
trophozoite stage of two strains of N. fowleri. In addition, the most active molecule was evaluated in
order to check the induction of programmed cell death (PCD) in the treated amoebae. Compound 3
showed good anti-Naegleria activity (61.45 ± 5.27 and 76.61 ± 10.84 µM, respectively) against the
two different strains (ATCC® 30808 and ATCC® 30215) and a good selectivity compared to the
cytotoxicity values (>300 µM). In addition, it was able to induce PCD, causing DNA condensation,
damage at the cellular membrane, reduction in mitochondrial membrane potential and ATP levels,
and ROS generation. Hence, naphthyridines fused with chromenes or chromenones could be potential
therapeutic agents against PAM in the near future.
Keywords: Naegleria fowleri; meningoencephalitis; naphthyridine derivatives; programmed cell death
1. Introduction
Primary amoebic meningoencephalitis (PAM), caused by infection from the free-living
amoeba parasite Naegleria fowleri, is a fatal central nervous disease that exhibits severe
meningitis and cranial pressure caused by inflammation of the brain [1]. This species,
commonly known as the “brain-eating amoeba”, is the only species of the Naegleria genus
associated with the infection of humans [2], mostly affecting healthy children and young
adults [3].
After the first reported case described by Carter and Fowler in 1965 [4], more than
430 cases have been successfully reported worldwide [5]. The USA is the country with the
Pharmaceuticals 2021, 14, 1013. https://doi.org/10.3390/ph14101013 https://www.mdpi.com/journal/pharmaceuticals
Pharmaceuticals 2021, 14, 1013 2 of 15
most cases reported at 156 cases [6], followed by Pakistan with 105 cases described until
2018 [6,7]. The incidence of reported cases of PAM has increased in recent years, and it is
still considered underdiagnosed due to the non-specific symptoms [8,9].
The infection is produced after the performance of water activities in warm water
bodies that present Naegleria. The trophozoites penetrate the olfactory nerve via the nasal
cavity. Once there, Naegleria migrate to the cribriform plate, cross it, and invade the central
nervous system [10]. The unspecific symptomatology includes seizures, stiff neck, bifrontal
headache or paralysis and appears within the first 9 days after exposure [11]. PAM cases
present a fast progression, with the death of the patient taking place between 1 and 18 days
after the appearance of the first symptom and a reported mortality rate of above 95% in the
reported cases [12,13].
Along with this fast progression, the lack of rapid clinical detection methods [14–16]
and the absence of specific therapy protocols make it even more difficult to face PAM
disease, showing a correlation with the high mortality rate reported [1]. Current experi-
mental therapy options involve miltefosine or amphotericin B, sometimes administrated
in combination with other medication (for example, with azoles or rifampin) or with con-
trolled hypothermia [17,18]. Despite the announcement of a successful PAM treatment
case [19–21], these compounds present undesired side effects such as nephrotoxicity or
even brain damage [22,23]. Hence, there is an urgent need to develop novel anti-Naegleria
treatments more efficiently with low cytotoxicity effects for the patient.
Coumarins and 2H-chromenes (Figure 1) are heterocyclic derivatives with a benzene
fused to a pyran [24–26]. They are present in a large number of natural products, and
both heterocycles constitute an important moiety in bioactive heterocycles with pharma-
cological properties [27], including anticancer drugs [27,28]. Therefore, these scaffolds
are very interesting substrates in the search for new drug candidates. The low toxicity
of natural products containing chromene and their broad pharmacological properties are
attractive features for medicinal chemists and a source of inspiration for the design of novel
therapeutic agents [27].
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ities [29]. In this sense, several naphthyridine derivatives present good pharmacological ac-
tivity with low toxicity [30]. In addition, among the most cited applications related to 1,8-
naphthyridines are antiparasitic [31,32], antibacterial [33,34], and antiviral [35–37] activities. 
Furthermore, naphthyridines fused with chromenes or chromenones present diverse 
biological activities such as antifungal, antimicrobial, and antibacterial [38]. 
In recent years, our collaborating group has developed the synthesis of fused 1,5 
naphthyridine derivatives such as chromeno 4,3-b 1,5 naphthyridine (I) and chromenone 
4,3-b 1,5 naphthyridine (II) and fused 1,8 naphthyridine derivatives such as chromeno  
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The naphthyridine (Figure 1) ring has gained attention, becoming an important
pharmacophore in the discovery of new biological agents due to its attractive biologi-
cal activities [29]. In this sense, several naphthyridine derivatives present good phar-
macological activity with low toxicity [30]. In addition, among the most cited appli-
cations related to 1,8-naphthyridines are antiparasitic [31,32], antibacterial [33,34], and
antiviral [35–37] activities.
Furthermore, naphthyridines fused with chromenes or chromenones present diverse
biological activities such as antifungal, antimicrobial, and antibacterial [38].
In recent years, our collaborating group has developed the synthesis of fused 1,5 naph-
thyridine derivatives such as chromeno 4,3-b 1,5 naphthyridine (I) and chromenone 4,3-b
1,5 naphthyridine (II) and fused 1,8 naphthyridine derivatives such as chromeno 4,3-b
1,8 naphthyridine (III) and chromenone 4,3-b 1,8 naphthyridine (IV). After studying these
Pharmaceuticals 2021, 14, 1013 3 of 15
compounds as topoisomerase I inhibitors and as antiproliferative agents, it was observed
that some of the compounds presented high enzymatic activity; however, no relevant
results were obtained in terms of antiproliferative activity [39].
With these considerations in mind, the anti-amoebic activity of a library of 24 fused
1,5 naphthyridine derivatives was tested against Naegleria fowleri. Moreover, further stud-
ies were carried out in the selected compounds in order to evaluate the induction of
programmed cell death (PCD).
2. Results
2.1. In Vitro Evaluation of Amoebicidal Activity and Cytotoxicity of Fused 1,5
Naphthyridine Derivatives
Among the selected compounds, 1,8 naphthyridines fused with chromene (Figure 2, 1
to 4) and chromenone rings (Figure 2, 5 to 10) and 1,5 naphthyridines fused with chromene
(Figure 2, 11 to 18) and chromenone rings (Figure 2, 19 to 24) were evaluated.
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rings. Compounds 11–18 correspond to 1,5 naphthyridines fused with chromene. Compounds 19–24 are 1,5 naphthyridines
fused with chromenone.
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Activity assays revealed that one of the evaluated compounds was able to eliminate
Naegleria fowleri trophozoites at low µM concentrations, shown in Table 1. Both compounds
stood out for their inhibitory concentration 50 (IC50) value (Figures 3 and S1), being more
selective than miltefosine (one of the reference drugs) [40].
Table 1. Inhibitory concentrations (IC50/IC90) of the evaluated compounds against the trophozoite stage of Naegleria fowleri
type strains ATCC® 30808™ and ATCC® 30215™, and cytotoxicity values (CC50) against murine macrophages J774A.1 strain
ATCC® TIB-67™. N/D indicates that values were not determinate. The selectivity index (SI) of the active compounds was
also calculated.













1 >100 N/D N/D N/D N/D N/D
2 >100 N/D N/D N/D N/D N/D
3 61.45 ± 5.27 76.61 ± 10.84 >300 >4.88 199.02 >200
4 >100 N/D N/D N/D N/D N/D
5 >100 N/D N/D N/D N/D N/D
6 >100 N/D N/D N/D N/D N/D
7 >100 N/D N/D N/D N/D N/D
8 >100 N/D N/D N/D N/D N/D
9 >100 N/D N/D N/D N/D N/D
10 >100 N/D N/D N/D N/D N/D
11 >100 N/D N/D N/D N/D N/D
12 >100 N/D N/D N/D N/D N/D
13 >100 N/D N/D N/D N/D N/D
14 >100 N/D N/D N/D N/D N/D
15 >100 N/D N/D N/D N/D N/D
16 >100 N/D N/D N/D N/D N/D
17 >100 N/D N/D N/D N/D N/D
18 >100 N/D N/D N/D N/D N/D
19 >100 N/D N/D N/D N/D N/D
20 >100 N/D N/D N/D N/D N/D
21 >100 N/D N/D N/D N/D N/D
22 >100 N/D N/D N/D N/D N/D
23 >100 N/D N/D N/D N/D N/D
24 >100 N/D N/D N/D N/D N/D
Amphotericin B 0.12 ± 0.03 0.16 ± 0.02 ≥200 ≥1652.89 0.35 ± 0.02 0.41 ± 0.12
Miltefosine 38.74 ± 4.23 81.57 ± 7.23 127.89 ± 8.85 3.301 89.47 ± 17.37 >200




Figure 3. Growth inhibition of Naegleria fowleri (ATCC®  30808™) trophozoites at 48 h at IC50 concentration. Compound 3 
(A) and negative control (B) with Naegleria fowleri (ATCC®  30215™) trophozoites at 48 h at IC50 concentration. Compound 3 
(C) and negative control (D). All images (40×) are representative of the cell population of treated amoeba and are based 
on the EVOS™ M5000 Imaging System, Invitrogen by Thermo Fisher Scientific, Madrid, Spain. Scale bars represent 75 µm. 
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Moreover, compound 3 (IUPAC nomenclature: (6aR, 7R, 12aR)-2-fluoro-7-phenyl-
6a,7,12,12a-tetrahydro-6H-chromeno 4,3-b 1,8 naphthyridine) was selected to continue
with PCD induction assays due to its good activity (IC50) and low toxicity.
2.2. Evaluation of PCD Induction by the Selected Compounds
These assays were performed in both strains of N. fowleri and revealed similar results
in all PCD experiments.
2.2.1. Double-Stain Assay for the Detection of Chromatin Condensation (Hoechst 33342/PI)
Cells treated with IC90 compound 3 revealed chromatin condensation after 24 h of in-
cubation, as shown in Figures 4 and S2 with the characteristically bright blue fluorescence.
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Pharmaceuticals 2021, 14, x FOR PEER REVIEW 5 of 14 
 
 
18 >100 N/D N/D N/D N/D N/D 
19 >100 N/D N/D N/D N/D N/D 
20 >100 N/D N/D N/D N/D N/D 
21 >100 N/D N/D N/D N/D N/D 
22 >100 N/D N/D N/D N/D N/D 
23 >100 N/D N/D N/D N/D N/D 
24 >100 N/D N/D N/D N/D N/D 
Amphotericin B 0.12 ± 0.03 0.16 ± 0.02 ≥200 ≥1652.89 0.35 ± 0.02 0.41 ± 0.12 
Miltefosine 38.74 ± 4.23 81.57 ± 7.23 127.89 ± 8.85 3.301 89.47 ± 17.37 >200 
Moreover, compound 3 (IUPAC nomenclature: (6aR, 7R, 12aR)-2-fluoro-7-phenyl-
6a,7,12,12a-tetrahydro-6H-chromeno 4,3-b 1,8 naphthyridine) was selected to continue 
with PCD induction assays due to its good activity (IC50) and low toxicity. 
2.2. Evaluation of PCD Induction by the Selected Compounds 
These assays were performed in both strains of N. fowleri and revealed similar results 
in all PCD experiments. 
2.2.1. Double-Stain Assay for the Detection of Chromatin Condensation (Hoechst 
33342/PI) 
Cells treated with IC90 compound 3 revealed chromatin condensation after 24 h of in-
cubation, as shown in Figure 4 and Figure S2 with the characteristically bright blue fluores-
cence. 
 
Figure 4. Naegleria fowleri (ATCC®  30808™) trophozoites incubated with IC90 of the evaluated 
compound 3 for 24 h. Negative control (A–B); compound 3 (C–D). Hoechst/PI stain is different in 
control cells, where no fluorescence is observed (B), and in treated cells, where the nuclei are intense 
blue and one of them shows red fluorescence inside (D). Images (40×) are representative of the cell 
population observed in the performed experiments. Images were obtained using an EVOS™ M5000 
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Fi re 4. Naegleria fowleri (ATCC® 30808™) trophozoites incubated with IC90 of the evaluated compound 3 for 24 h.
Negative control (A,B); compound 3 (C,D). Hoechst/PI stain is different in control cells, where no fluore cence is observed
(B), and in treated cells, where the nuclei are intense blue and one of them shows red fluorescence inside (D). Images (40×)
are representative of the cell population observed in the performed experiments. Images were obtained using an EVOS™
M5000 Imaging System, Invitrogen by Thermo Fisher Scientific, Madrid, Spain. Scale bars represent 75 µm.
2.2.2. Plasma Membrane Permeability (SYTOX Green)
Plasmatic membrane damage was caused by the selected compound after IC90 incuba-
tion for 24 h. Intense green fluorescence could be observed inside cells (Figures 5 and S3).
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2.2.4. Analysis of Mitochondrial Function Disruption 
The evaluated compound disrupted the mitochondrial membrane potential in 
treated cells, which is shown as green fluorescence (Figure 7 and Figure S5) corresponding 
to the monomeric form of JC-1 dye. To confirm mitochondrial damage, the ATP produc-
tion level was evaluated (Figure 8). 
Figure 6. I crease in intracellular ROS levels (red fluoresn ce) caused by the addition of compound 3 (C,D) at IC90 after
24 h of i cubation with Naegleria fowleri (AT C® 3080 ). Negative control (A,B). The evaluat d compound was adde to
the cells and exposed to CellROX® Deep Red (5 µ , 30 min) at 37 ◦C in the dark. Images (40×) are representative of the
cell population observed in the performed experiments. Images were obtained using an EVOS™ M5000 Imaging System,
Invitrogen by Thermo Fisher Scientific, Madrid, Spain. Scale bars represent 75 µm.
2.2.4. Analysis of Mitochondrial Function Disruption
The evaluated compound disrupted the mitochondrial membrane potential in treated
cells, which is shown as green fluorescence (Figures 7 and S5) corresponding to the
monomeric form of JC-1 dye. To confirm mitochondrial damage, the ATP production
level was evaluated (Figure 8).
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Figure 8. ATP levels in relative percentages compared to the negative control in Naegleria fowleri
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of th e m asurements. The results show a decr se in the ATP l vel following treatm nt with
comp und 3 of 84.90% compared to th negative co trol (cells without treatment).
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3. Discussion
In this study, the activity of different 1,5 naphthyridine and 1,8 naphthyridine deriva-
tives against the brain-eating amoeba Naegleria fowleri was evaluated. Moreover, some of
these molecules have already shown good inhibitory antiparasitic activity against other pro-
tozoa such as Leishmania [41] as well as antiproliferative activity against different cancer cell
lines [39,42]. Compound 3 showed good anti-Naegleria activity against two different strains
(ATCC® 30808 and ATCC® 30215) and a good selectivity compared to the cytotoxicity
values against a murine macrophage cell line (Table 1).
On the other hand, Cárdenas-Zuñiga and colleagues described a PCD/apoptosis-like
process in Naegleria fowleri and the metabolic events that these cells present. Among them,
the presence of blebs, DNA condensation, ROS, and electron-dense granules was observed
by the authors [43].
Our laboratory is not only focused on the search for new active molecules against
the deadly Naegleria fowleri but is also concerned with the avoidance of non-desirable side
effects that could result in inefficient management of the disease. Compound 3-treated
amoebae showed chromatin condensation, plasma membrane damage, increased levels
of ROS, and mitochondrial dysfunction after 24 h, all of which are compatible with the
induction of the PCD process. This type of cell death, which avoids the induction of
inflammatory reactions that are characteristic of necrosis [44], is the most desirable one in
the search for anti-amoebic compounds which present lower side effects and a safer profile
in therapy protocols.
In addition, these compounds have previously been described as topoisomerase I
inhibitors [39,42]. The genome data of Naegleria fowleri have recently been published [45,46],
showing the presence of DNA topoisomerase 1-like gene (NF0087810 (https://www.
uniprot.org/uniprot/A0A6A5BG47 (accessed on 28 September 2021)) [47]. Therefore, the
inhibition of one of the key proteins for the viability of the cell could be the reason for the
anti-Naegleria activity of the evaluated compounds. Nevertheless, further studies should
be developed in order to check cellular targets affected by the evaluated compound 3.
Moreover, naphthyridines and their derivatives have been previously reported to
inhibit acetylcholinesterases and have been proposed as interesting anti-Alzheimer lead
compounds. Hence, these molecules should be able to cross the brain–blood barrier,
supporting their potential as anti-PAM agents. However, BBB crossing by these compounds
and their in vivo efficacy should be further verified in experimental animal studies in the
near future [48].
4. Materials and Methods
4.1. Amoebic Strains and Cell Line Maintenance
Two American Type Culture Collection strains of Naegleria fowleri, ATCC 30808 and
ATCC 30215, were used to perform in vitro evaluation of the compounds (LG Promochem,
Barcelona, Spain). Amoebae were axenically grown at 37 ◦C in 2% (v/w) Bacto Casitone
medium (Thermo Fisher Scientific, Madrid, Spain) supplemented with 10% (v/v) fetal
bovine serum (FBS) (Biowest, VWR, Barcelona, Spain), 0.3 µg/mL of Penicillin G Sodium
Salt (Sigma-Aldrich, Madrid, Spain), and 0.5 mg/mL of streptomycin sulphate (Sigma-
Aldrich, Madrid, Spain). Naegleria fowleri cultures were conserved in a biological security
facility of level 3 at the Instituto Universitario de Enfermedades Tropicales y Salud Pública
de Canarias following the Spanish government’s biosafety guidelines for this pathogen
with the minimum number of passages possible to avoid loss of pathogenicity.
Cytotoxicity assays were performed with a murine macrophage cell line (ATCC®
TIB-67) grown in Dulbecco’s Modified Eagle’s medium (GIBCO, Thermo Fisher Scientific)
(DMEM, w/v) supplemented with 10% (v/v) FBS and 10 µg/mL of gentamicin (Sigma-
Aldrich, Madrid, Spain). Cells were cultured in 5% CO2.
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4.2. Chemistry General Experimental Information
All reagents from commercial suppliers were used without further purification. All
solvents were freshly distilled before use from appropriate drying agents. All other reagents
were recrystallized or distilled when necessary. Reactions were performed under a dry ni-
trogen atmosphere. Analytical thin layer chromatography (TLC) was performed with silica
gel 60 F254 plates. Visualization was accomplished by UV light. Column chromatography
was carried out using silica gel 60 (230–400 mesh ASTM). Melting points were determined
with an Electrothermal IA9100 Digital Melting Point Apparatus without correction. NMR
spectra were obtained on Bruker Avance 400 MHz and Varian VXR 300 MHz spectrom-
eters and recorded at 25 ◦C. Chemical shifts for 1H NMR spectra are reported in ppm
downfield from TMS, chemical shifts for 13C NMR spectra are recorded in ppm relative to
internal deuterated chloroform (δ = 77.2 ppm for 13C), and chemical shifts for 19F NMR
are reported in ppm downfield from fluorotrichloromethane (CFCl3). Coupling constants
(J) are reported in Hertz. The terms m, s, d, t, and q refer to multiplet, singlet, doublet,
triplet, and quartet, respectively. 13C NMR and 19F NMR were broadband decoupled from
hydrogen nuclei. High-resolution mass spectra (HRMS) were measured by EI method with
an Agilent LC-Q-TOF-MS 6520 spectrometer.
4.3. Compound Purity Analysis
All synthesized compounds were analyzed by HPLC to determine their purity. The
analyses were performed on an Agilent 1260 infinity HPLC system (C-18 column, Hypersil,
BDS, 5 µm, 0.4 × 25 mm). All the tested compounds were dissolved in dichloromethane,
and 1 µL of the sample was loaded onto the column. Ethanol and heptane were used as
mobile phases, and the flow rate was set at 1.0 mL/min. The maximal absorbance at the
range of 190−625 nm was used as the detection wavelength. The purity of all the tested
compounds was >95%, which met the purity requirement of the journal.
4.4. In Vitro Amoebicidal Activity
A colorimetric assay based on the alamarBlue® reagent was used to evaluate the
inhibitory concentration 50 (IC50) of the compound. Briefly, 50 µL of Naegleria fowleri cells
from a 2 × 105 cells/mL stock solution was seeded in each well of a 96-well microtiter plate
(Thermo Fisher Scientific). After that, 50 µL of serial dilutions of the compound (in the
same Naegleria culture medium) was added to each well. The negative control consisted
of cells with the culture medium alone. Finally, 10% of the final volume of alamarBlue®
reagent was placed into the plate. After incubation for 48 h at 37 ◦C under slight agitation,
plates were analyzed with an Enspire® Multimode Plate Reader (Perkin Elmer, Madrid,
Spain) using a wavelength of 570 nm and a reference wavelength of 630 nm.
The data were analyzed using GraphPad Prism 9.0.0 software program (GraphPad
Software, San Diego, CA, USA). The anti-amoebic activity was expressed as an IC50 (in-
hibitory concentration 50) value which was calculated by performing a nonlinear regression
analysis with a 95% confidence limit. All experiments were carried out in triplicate and
mean values were calculated. A paired two-tailed t-test was used for analysis of the data.
Values of p < 0.05 were considered significant.
4.5. In Vitro Cytotoxicity
The CC50 (cytotoxic concentration 50) of the compound was evaluated using a murine
macrophage cell line (ATCC® TIB-67), as previously described [11]. Briefly, cells were
incubated for 4 h with different concentrations of compound 3 at 37 ◦C in a 5% CO2
atmosphere.
4.6. Analysis of Programmed Cell Death (PCD) Induction
For the evaluation of programmed cell death induction by compound 3 in Naeg-
leria fowleri, the ATCC® 30808™ strain was used. Amoebae were incubated with the
IC90 (inhibitory concentration 90%) of the compound to later evaluate the presence of
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some of the PCD characteristic metabolic events [49] with different stains, following
the manufacturer’s instructions.
4.6.1. Detection of Chromatin Condensation
A double-stain apoptosis detection kit (Hoechst 33342/Propidium Iodide (PI)) (Life
Technologies) was used in this assay. Briefly, 5 × 105 cells/mL were incubated with the
IC90 of the compound for 24 h at 37 ◦C in a 96-well plate. Images were obtained after
15 min of incubation of the dye using an EVOS™ M5000 Imaging System (Invitrogen by
Thermo Fisher Scientific).
This kit allows the differentiation of three type of cells in the culture. Those with red
and low blue fluorescence correspond to dead cells (as PI is able to enter the cells), and live
cells will show low blue fluorescence, whereas cells undergoing PCD will show an intense
blue fluorescence (corresponding to the Hoechst 33342 stain that detects condensed chromatin).
4.6.2. Plasma Membrane Alteration
Evaluation of the plasma membrane integrity was carried out with the SYTOX Green
assay (Life Technologies, Madrid, Spain). For the experiment, IC90 of the compound was
incubated with the cells (5 × 105 cells/mL) for 24 h at 37 ◦C. Afterwards, the dye was added,
and after 15 min of incubation, images were taken using the EVOS™ M5000 Imaging System
(Invitrogen by Thermo Fisher Scientific). The SYTOX Green dye shows green fluorescence
when binding to the DNA of cells with plasma membrane damage.
4.6.3. Reactive Oxygen Species (ROS) Generation
The CellROX Deep Red fluorescent assay (Thermo Fisher Scientific) was used for the
evaluation of ROS generation. Firstly, Naegleria fowleri trophozoites (5 × 105 cells/mL)
were incubated with the IC90 of compound 3 at 37 ◦C for 24 h. After that, the CellROX dye
was added and incubated for 30 min in the same conditions. Finally, red fluorescence was
observed in an EVOS™ M5000 Imaging System (Invitrogen by Thermo Fisher Scientific)
corresponding to the presence of ROS.
4.6.4. Analysis of Mitochondrial Function Disruption
Two different commercial kits were used for the evaluation of the mitochondrial
function condition as described below.
Mitochondrial Membrane Potential
The collapse of an electrochemical gradient across the mitochondrial membrane in the
treated cells during PCD induction was evaluated with the JC-1 Mitochondrial Membrane
Potential Detection Kit (Cayman Chemicals Vitro SA, Madrid, Spain). Amoebae were
incubated with the IC90 of the evaluated compound for 24 h at 37 ◦C and the JC-1 dye was
added later.
This kit allows to distinguish between two different cell types: live cells will show only
red fluorescence as the dye appears as J-aggregate complexes, whereas cells undergoing
PCD will show both red and green fluorescence as the JC-1 remains in its monomeric form.
Evaluation of ATP Levels
For the ATP level measurement, the CellTiter-Glo Luminescent Cell Viability Assay
(PROMEGA BIOTECH IBÉRICA S.L, Madrid, Spain) was used according to the manufac-
turer’s instructions. The effect of compound 3 on ATP production was evaluated after the
incubation of 5 × 105 cells/mL with the previously calculated IC90 of the compound.
5. Conclusions
In conclusion, (6aR, 7R, 12aR)-2-fluoro-7-phenyl-6a,7,12,12a-tetrahydro-6H-chromeno
4,3-b 1,8 naphthyridine named compound 3 in this study, showed high activity against
the two different Naegleria fowleri strains included in this study, inducing PCD processes
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and showing low toxicity. Therefore, this compound could be a good candidate for future
in vivo assays to develop new PAM therapeutic protocols.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14101013/s1, Figure S1. N. fowleri (ATCC30808 and ATCC30215) trophozoites incubated
with the IC50 of Compound 3 and Negative control; Figure S2. Higher magnification of Figure 4;
Figure S3. Higher magnification of Figure 5; Figure S4. Higher magnification of Figure 6; Figure S5.
Higher magnification of Figure 7.
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